Patent intelligence · US
US 10080770
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
Patent details — US 10080770
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 25, 2018
- Expiration
- Sep 20, 2038
- Applicant
- RegenLab USA LLC
- Claims
- 28
- CPC classes
- A61K, A61K2300/00, A61K2800/87, A61K35/14
Quick answer
US 10080770 (Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo) is held by RegenLab USA LLC. Status: granted. Granted Sep 25, 2018. Expires Sep 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RegenLab USA LLC
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K2300/00, A61K2800/87, A61K35/14, A61K35/15, A61K35/16
More from RegenLab USA LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10080770?
US 10080770 (Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo) is held by RegenLab USA LLC. Status: granted. Granted Sep 25, 2018. Expires Sep 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10080770?
RegenLab USA LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10080770 expire?
Our index shows an expiration date of Sep 20, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.